Company intelligence / Profile preview

NC Medical Research

Tokyo or nearby area (exact city not specified), Tokyo Prefecture (inferred from headquarters address on Japanese site), Japanimr.org ↗

Ownership: Private
Development stage: Other

Overview

NC Medical Research focuses on developing cell-based therapies to regenerate nerves damaged by stroke and similar conditions. Their lead program, NCS‑01, has entered clinical trials in the United States following FDA IND acceptance in July 2019 and trial initiation in February 2020. The company aims to leverage natural healing mechanisms for neurological repair.[1][2]

Therapeutic areas: Neurology
Modalities: Cell therapyRegenerative medicine therapyBiologic (inferred from cell-based regenerative approach)
Industry: Biotech

Drug pipeline

1 asset

NCS-01

Partnerships

Not publicly disclosed as of June 2025.

Beyond the preview

Go deeper on NC Medical Research.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NC Medical Research.

Explore the full profile